Internship

ML Research Intern

PhD

Confirmed live in the last 24 hours

Genesis Therapeutics

Genesis Therapeutics

51-200 employees

AI-driven drug discovery for pharmaceuticals

AI & Machine Learning
Biotechnology

Burlingame, CA, USA

Category
Computational Biology
Genomics
Biology Lab & Research
Biology & Biotech
Required Skills
Machine Learning

You match the following Genesis Therapeutics's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Currently enrolled in a PhD program in Computer Science, Machine Learning, or related fields.
  • Strong background in machine learning, deep learning, and/or related areas.
  • A deep thinker who reasons from first principles over pattern matching.
  • Interested in learning about biochemistry and the drug development process.
Responsibilities
  • Lead a research project, which will be broadly focused on a problem related to generative or predictive modeling of molecular systems.
  • Navigate the latest deep learning literature, extracting insights from generative modeling in adjacent domains (language, images, 3D graphics, etc.), develop novel models and training techniques for molecular data, and communicate your findings to the team.
  • Carefully design and run experiments at scale to validate most promising approaches and hypotheses.

Genesis Therapeutics focuses on accelerating the development of new medicines using artificial intelligence in the drug discovery sector. The company employs a method that combines 3D spatial graph modeling and advanced molecular simulation to identify potential drug candidates. This approach enables the exploration of new chemical spaces and the discovery of novel protein targets, which can lead to important new medicines. Unlike many competitors, Genesis Therapeutics operates on a business-to-business model, partnering with other biotech and pharmaceutical companies, such as Eli Lilly, to provide its AI-driven drug discovery services. The company generates revenue through upfront payments and potential future earnings based on the success of the drugs developed through its platform. Genesis Therapeutics aims to transform the drug discovery process and bring critical new medicines to market.

Company Size

51-200

Company Stage

Series B

Total Funding

$272.5M

Headquarters

Burlingame, California

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with NVIDIA enhances GEMS platform for targeting undruggable diseases.
  • $224 million equity investment boosts research and development capabilities.
  • Recognition as a 'Fierce 15' company underscores AI's role in breakthrough therapeutics.

What critics are saying

  • Competition from AI-driven companies like Insilico Medicine and Exscientia is increasing.
  • Over-reliance on partnerships could lead to financial instability if drugs aren't successful.
  • Rapid AI advancements may render current models like GEMS obsolete without updates.

What makes Genesis Therapeutics unique

  • Genesis Therapeutics uses AI to accelerate drug discovery with 3D spatial graph modeling.
  • The GEMS platform integrates deep learning, molecular simulations, and generative AI for drug design.
  • Strategic partnerships with Eli Lilly and Gilead highlight Genesis' industry collaboration strength.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive salary

Equity

Medical, dental, & vision insurance

401(k) program

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

3%

2 year growth

0%
Genetic Engineering & Biotechnology News
Dec 18th, 2024
Genesis Therapeutics Secures Nvidia Investment Boost

Nvidia’s venture arm, NVentures, has increased its investment in AI drug discovery firm Genesis Therapeutics. Genesis, founded by Evan Feinberg, has raised over $300 million, including a $200 million Series B in 2023. The collaboration aims to enhance Genesis' AI platform, GEMS, for drug discovery. Genesis is also working with Gilead, Eli Lilly, and Genentech on various projects. The company plans to expand its workforce beyond its current 80 employees.

Finsmes
Nov 14th, 2024
Genesis Therapeutics Receives Equity Investment From NVIDIA

Genesis Therapeutics receives equity investment from NVIDIA.

BioPharmaTrend
Nov 13th, 2024
Genesis Therapeutics, NVIDIA Partner; $200M Boost

Genesis Therapeutics has partnered with NVIDIA to enhance its AI platform, GEMS, for drug discovery. This collaboration is supported by additional funding from NVentures, NVIDIA's venture capital arm, following its participation in Genesis' $200 million Series B financing in August 2023. The partnership aims to optimize computational methods like equivariant neural networks to analyze complex 3D molecular structures, targeting diseases with high unmet needs and previously undruggable targets.

ProHost Biotech
Sep 10th, 2024
Gilead Therapeutics and Genesis Therapeutics Announced Strategic Collaboration to Discover and Develop Novel Therapies

Gilead Sciences (GILD) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets.

Pipeline Review
Sep 10th, 2024
Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies

Gilead and Genesis Therapeutics announce strategic collaboration to discover and develop novel therapies.